News | December 20, 2013

New Data Show Seno Medical Instruments' Imagio May Help Reduce Negative Biopsies for Breast Cancer

December 20, 2013 — Seno Medical Instruments Inc., the company pioneering opto-acoustic imaging as a tool to improve the process of diagnosing breast cancer, announced preliminary information from a feasibility study of its Imagio breast imaging device. Results from the feasibility study suggest that information from Imagio, beyond that available from traditional breast ultrasound, may be helpful in assisting physicians in their decisions whether to recommend biopsies for women with suspicious breast masses. The data were presented at the Radiological Society of America Annual Meeting (RSNA 2013).

Imagio combines an imaging technology based on light-in and sound-out called "opto-acoustics" with traditional ultrasound. The opto-acoustic images provide a unique blood map in and around suspicious breast masses. Unlike other imaging modalities, Imagio doesn't expose patients to potentially harmful ionizing radiation (X-rays) or injectable contrast agents.

"Given these early results, I believe that opto-acoustics could potentially spare some BI-RADS 4a cases and some BI-RADS 4b cases from needing to undergo biopsies," said Kenneth Kist, M.D., associate professor of Radiology, University of Texas Health Science Center, San Antonio, and study investigator. "This could represent a significant advance in the diagnostic path for breast cancer and I look forward to seeing the results of the ongoing U.S. Pivotal Study."

The BI-RADS classification is used by radiologists to predict the probability of malignancy of a breast mass based on imaging results. A BI-RADS 3 mass only carries up to a 2 percent chance of being cancerous. Patients with masses in the BI-RADS 3 category can safely wait to see if the mass changes or grows. A BI-RADS 4a mass is considered to have more than a 2 percent but less than or equal to 10 percent chance of being cancerous, and a BI-RADS 4b mass is considered to carry from greater than 10 percent to less than or equal to 50 percent risk of malignancy. Patients whose masses are deemed BI-RADS 4a or higher will almost always undergo a core needle or surgical biopsy.

For this study (Abstract LL-BRS-WE5B), five blinded readers independently assessed Imagio images from 73 patients with 74 breast masses. All of the masses were biopsied to provide a gold-standard comparator. Readers were blinded to the subjects' medical history, biopsy report, histology report, clinical records and follow-up. All 34 detected cancer masses remained at their original BI-RADS classification.

In the 40 remaining benign masses, downgrades to BI-RADS 3 were achieved in 12 of 22 original BI-RADS 4a diagnoses as a result of opto-acoustics. Three of 13 BI-RADS 4b masses were downgraded to BI-RADS 3.

Each year in the United States, 1.7 million women undergo core needle or surgical breast biopsies after a suspicious mass is found through breast imaging or self-exams. However, up to four out of five of these biopsies reveal benign pathology.

A separate electronic exhibit (Abstract LL-BRE2487) providing an overview of opto-acoustic technology was also displayed throughout the meeting.

"These early results underscore the potential of opto-acoustic imaging technology which we believe represents a significant step forward in cancer diagnosis," said Thomas Stavros, M.D., FACR, FSRU, FRANZCR, medical director, Seno Medical Instruments. "This feasibility study shows that Imagio has potential to lead to better outcomes for women and fewer biopsies. We are working diligently with 16 leading breast imaging centers across the U.S. to complete our Imagio Pivotal Study that will form the basis of our Premarket Approval Application with the U.S. Food and Drug Administration."

For more information: www.senomedical.com

Related Content

DenseBreast-info.org Launches European-Focused Education Coalition
News | Breast Density | February 19, 2018
DenseBreast-info.org (DB-I) announced plans for international expansion with specialized content for Europe and...
AHRA and Canon Medical Systems Announce 2017 Putting Patients First Grant Winners
News | Patient Engagement | February 14, 2018
The Association for Medical Imaging Management (AHRA) and Canon Medical Systems recently announced the tenth annual...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Digisonics Customers Expand OB Ultrasound Reporting Systems for Improved Workflow Efficiency
News | Ultrasound Imaging | February 06, 2018
February 6, 2018 – Oregon Health and Science University in Portland, Ore., University of Utah Medical Center in Salt
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
Small-Cell Lung Cancer Patients Face Barriers to Standard-of-Care Treatment
News | Lung Cancer | January 29, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the...
ASE Opens Enrollment for ImageGuideEcho Registry
News | Cardiovascular Ultrasound | January 29, 2018
January 29, 2018 — The American Society of Echocardiography (ASE) announced that ImageGuideEcho, a module under the I
Overlay Init